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Low concordance of multiple variant-calling
pipelines: practical implications for exome and
genome sequencing
Jason O’Rawe1,2, Tao Jiang3, Guangqing Sun3, Yiyang Wu1,2, Wei Wang4, Jingchu Hu3, Paul Bodily5, Lifeng Tian6,
Hakon Hakonarson6, W Evan Johnson7, Zhi Wei4, Kai Wang8,9* and Gholson J Lyon1,2,9*
Abstract
Background: To facilitate the clinical implementation of genomic medicine by next-generation sequencing, it will
be critically important to obtain accurate and consistent variant calls on personal genomes. Multiple software tools
for variant calling are available, but it is unclear how comparable these tools are or what their relative merits in
real-world scenarios might be.
Methods: We sequenced 15 exomes from four families using commercial kits (Illumina HiSeq 2000 platform and
Agilent SureSelect version 2 capture kit), with approximately 120X mean coverage. We analyzed the raw data using
near-default parameters with five different alignment and variant-calling pipelines (SOAP, BWA-GATK, BWA-SNVer,
GNUMAP, and BWA-SAMtools). We additionally sequenced a single whole genome using the sequencing and
analysis pipeline from Complete Genomics (CG), with 95% of the exome region being covered by 20 or more
reads per base. Finally, we validated 919 single-nucleotide variations (SNVs) and 841 insertions and deletions
(indels), including similar fractions of GATK-only, SOAP-only, and shared calls, on the MiSeq platform by amplicon
sequencing with approximately 5000X mean coverage.
Results: SNV concordance between five Illumina pipelines across all 15 exomes was 57.4%, while 0.5 to 5.1% of
variants were called as unique to each pipeline. Indel concordance was only 26.8% between three indel-calling
pipelines, even after left-normalizing and intervalizing genomic coordinates by 20 base pairs. There were 11% of
CG variants falling within targeted regions in exome sequencing that were not called by any of the Illumina-based
exome analysis pipelines. Based on targeted amplicon sequencing on the MiSeq platform, 97.1%, 60.2%, and 99.1%
of the GATK-only, SOAP-only and shared SNVs could be validated, but only 54.0%, 44.6%, and 78.1% of the GATK-
only, SOAP-only and shared indels could be validated. Additionally, our analysis of two families (one with four
individuals and the other with seven), demonstrated additional accuracy gained in variant discovery by having
access to genetic data from a multi-generational family.
Conclusions: Our results suggest that more caution should be exercised in genomic medicine settings when
analyzing individual genomes, including interpreting positive and negative findings with scrutiny, especially for
indels. We advocate for renewed collection and sequencing of multi-generational families to increase the overall
accuracy of whole genomes.
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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more signiﬁcant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the ﬁeld of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as tod y's DNA sequencing techn logy has the potent al to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to mov forward towards expanded clinical use of thi
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
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admission, he was noted to be oriented to name, place, and
time, but no other cognitive testing was done at that time.
Hospital Course
Upon admission, T. displayed mood instability, poor judg-
ment, and verbal and physical threats to harm peers and
staff. He was extremely assaultive and aggressive. He was
unable to use words to express his feelings, which resulted
in him spitting, biting, kicking, cursing, and hitting during
times of crisis. He was placed on constant observation (1:1)
upon admission due to the severity of his aggression. He re-
ported occasional nightmares, was described as hypervigi-
lant around all staff, and occasionally had early insomnia.
Medical workup, including physical exam, blood
chemistries, neurological examination, and an MRI of the
spine were within normal limits.
T. remained aggressive in the hospital for many months
(Fig. 1). His treatment consisted of behavioral and pharma-
cologic intervention used in combination. Over the final five
months of hospitalization, the patient showed remarkable
improvements, with less overall number of incidents and
with less violence in each episode (Fig. 1).
There was never a time during this greater !8-month hos-
pitalization in which there was any evidence of a bipolar or
any psychotic disorder. During his time in the hospital, the
patient did not display sexually inappropriate or fire-setting
behaviors.
Pharmacological Management
After admission, T. was gradually tapered off of risperi-
done 3 mg, clozapine 200 mg, and valproic acid 750 mg. A
trial of lithium was started but discontinued after anger and
behavioral problems notably increased. He was initially
given chlorpromazine only on an as-needed basis, with doses
ranging from 25–100 mg by mouth (PO) or intramuscular
(IM), usually given once or twice per week. Other medica-
tions included diphenhydramine 100 mg PO or 25 mg IM
and risperidone M tabs 1 mg PO as needed. These were given
also 1–2 times per week during the first several months.
Standing doses of chlorpromazine were added, initially 25
mg three times daily (tid) and increased to 50 mg four times
daily, which caused substantial sedation. Later, chlorpro-
mazine was lowered, and sertraline was begun to target the
aggression (Siegel et al. 2007). Sertraline was titrated up
slowly to a total dose of 125 mg daily.
Notably, despite a childhood diagnosis of ADHD, T. had
never had a trial of stimulants, as far as could be determined
from available records and from grandparents. A trial of im-
mediate-release methylphenidate was started and titrated up
to 15 mg PO tid with no adverse effects. There was a dra-
matic improvement in his attention, concentration, and hy-
peractivity. Guanfacine (titrated up to a total dose of 2 mg
daily) was added to address residual impulsivity and irri-
tability, which also was beneficial in controlling this behav-
ior. Towards the end of T.’s hospital course, in order to sim-
plify his medication regimen, the immediate release
methylphenidate was changed to extended release Concerta
54 mg daily, which he also tolerated well. 
During tapering of the chlorpromazine, T. was noted to
have some pill-rolling, shoulder shrugging, and stiff gait,
which was felt to be due to withdrawal dyskinesia. Given
the extrapyramidal symptoms and emergence of a possible
withdrawal dyskinesia, it was decided to slow the taper of
chlorpromazine, and he was discharged on a very small dose
of chlorpromazine. Desmopressin was given for enuresis
with resolution of symptoms.
During the hospitalization, T.’s height increased from five
feet two inches to five feet four and one half inches, and his
weight increased slightly from 134.5 lbs to 137 lbs.
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FIG. 1. Number of incidents including crisis team interventions (calls overhead for assistance), manual restraints, and ur-
gent medications (by mouth or intramuscular) for each month during the course of this patient’s hospitalization.
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Chief Complaint and Presenting Problem
T., A 12-YEAR-OLD Hispanic boy, was transferred to a statechildren’s psychiatric hospital for management of “be-
havioral problems.” He admitted to getting angry and break-
ing things and complained of insomnia, nightmares, and fre-
quent nervousness.
History of Present Illness
T. was reported to have a long history of aggressive, as-
saultive, and unpredictable behavior, angry and irritable
moods, impulsivity, hyperactivity, enuresis, and a history of
nightmares and flashbacks. T. had experienced four prior
psychiatric hospitalizations. Prior to the current transfer,
during an approximately three-month stay at a private hos-
pital, T. was reported to have become increasingly aggres-
sive, assaultive, and impulsive, requiring frequent as-needed
medications including intramuscular injections of lo-
razepam, haloperidol, and chlorpromazine. Lorazepam and
other benzodiazepines were thought to cause disinhibition
and worsened his behaviors. Upon transfer to the state chil-
dren’s psychiatric hospital, T. carried diagnoses of mixed
bipolar disorder, thyroid abnormalities, asthma, and possi-
ble fetal alcohol syndrome.
Upon transfer, T.’s medications included risperidone 3 mg,
clozapine 200 mg, valproic acid 750 mg, guanfacine 4 mg, and
desmopressin 0.6 mg. His as-needed medications were chlor-
promazine 50 mg every two hours, with a maximum of four
doses daily, Benadryl 50 mg every four hours, and albuterol
inhaler two puffs every four hours with a maximum of four
doses daily. The clozapine dose had been adjusted downward
in the previous hospital due to sedation and drooling.
Past Psychiatric History
T. had been hospitalized four times, at ages 6, 7, 8 and 12;
each lasted 1–3 months. The last hospitalization led to trans-
fer to the current state hospital. From age 7 to the present,
T. lived primarily in foster care or at a residential treatment
center when he was not in the hospital. Prior diagnoses given
on discharge summaries included intermittent explosive dis-
order, oppositional defiant disorder, rule-out bipolar mood
disorder not otherwise specified (NOS), and rule-out con-
duct disorder. It was noted that hospitalizations were usu-
ally triggered when foster or group home parents went on
vacation or when T. had a rare visitation with his biological
mother.
T. was first hospitalized at age 6 for increasing aggression
and reportedly smearing feces and fondling his younger sib-
ling. He was also noted to have no friends and to frequently
threaten to kill himself when limits were set. There were also
sexualized behaviors towards his younger stepbrothers; his
father and stepmother described him as “never happy,”
stealing food and money, lying when caught, and hoarding
food. He was also fascinated by guns and violence. All of the
above led to suspicion of neglect and physical and/or sex-
ual abuse of T. at an earlier age. T.’s parents requested out
of home placement for him at age 7 for many reasons, in-
cluding fear for the safety of the other children, and he was
placed in therapeutic foster care.
T.’s second hospitalization occurred at age 7 due to an in-
crease in aggressive behavior. He also reported experiencing
command auditory hallucinations telling him to hurt people.
His thinking was disorganized, characterized by strained
reasoning, poor judgment, and suspicion. It was noted that
he often misinterpreted is environment a d his interaction
with others, and preferred to isolate himself from his peers.
After about two weeks of medication adjustments, thera-
peutic milieu, and individual therapy, he began to show im-
provement in his ability to resist assaulting others. His di-
agnosis at discharge was psychotic disorder, NOS.
The third hospitalization occurred at age 8, also for acting
out and aggressive behavior, although the treatment records
were unavailable from this hospitalization. He was appar-
ently discharged to a residential treatment center at the end
of this hospitalization.
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Chief Complaint and Presenting Problem
T., A 12-YEAR-OLD Hispanic boy, was transferred to a statechildr n’s psychiatric hospital for management of “be-
havioral problems.” He admitted to getting angry and break-
ing t ings and compl i ed of i somnia, nightmares, and f e-
quent nervousn s .
History of Present Illness
T. was reported to have a long history of aggressive, as-
saultive, and unpredictable behavior, angry and irritable
moods, impulsivity, hyperactivity, enuresis, and a history of
nightmares and flashbacks. T. had experienced four prior
psychiatric hospitalizations. Prior to the current transfer,
during an approximately three-month stay at a private hos-
pital, T. was reported to have become increasingly aggres-
sive, assaultive, and impulsive, requiring frequent as-needed
medications including intramuscular injections of lo-
razepam, haloperidol, and chlorpromazine. Lorazepam and
other benzodiazepines were thought to cause disinhibition
and worsened his behaviors. Upon transfer to the state chil-
dren’s psychiatric hospital, T. carried diagnoses of mixed
bipolar disorder, thyroid abnormalities, asthma, and possi-
ble fetal alcohol syndrome.
Upon transfer, T.’s medications included risperidone 3 mg,
clozapine 200 mg, valproic acid 750 mg, guanfacine 4 mg, and
desmopressin 0.6 mg. His as-needed medications were chlor-
promazine 50 mg every two hours, with a maximum of four
doses daily, Benadryl 50 mg every four hours, and albuterol
inhaler two puffs every four hours with a maximum of four
doses daily. The clozapine dose had been adjusted downward
in the previous hospital due to sedation and drooling.
Past Psychiatric History
T. had been hospitalized four times, at ages 6, 7, 8 and 12;
each lasted 1–3 months. The last hospitalization led to trans-
fer to the current state hospital. From age 7 to the present,
T. lived primarily in foster care or at a residential treatment
center when he was not in the hospital. Prior diagnoses given
on discharge summaries included intermittent explosive dis-
order, oppositional defiant disorder, rule-out bipolar mood
disorder not otherwise specified (NOS), and rule-out con-
duct disorder. It was noted that hospitalizations were usu-
ally triggered when foster or group home parents went on
vacation or when T. had a rare visitation with his biological
mother.
T. was first hospitalized at age 6 for increasing aggression
and reportedly smearing feces and fondling his younger sib-
ling. He was also noted to have no friends and to frequently
threaten to kill himself when limits were set. There were also
sexualized behaviors towards his younger stepbrothers; his
father and stepmother described him as “never happy,”
stealing food and money, lying when caught, and hoarding
food. He was also fascinated by guns and violence. All of the
above led to suspicion of neglect and physical and/or sex-
ual abuse of T. at an earlier age. T.’s parents requested out
of home placement for him at age 7 for many reasons, in-
cluding fear for the safety of the other children, and he was
placed in therapeutic foster care.
T.’s second hospitalization occurred at age 7 due to an in-
crease in aggressive behavior. He also reported experiencing
command auditory hallucinations telling him to hurt people.
His thinking was disorganized, characterized by strained
reasoning, poor judgment, and suspicion. It was noted that
he often misinterpreted his environment and his interaction
with others, and preferred to isolate himself from his peers.
After about two weeks of medication adjustments, thera-
peutic milieu, and individual therapy, he began to show im-
provement in his ability to resist assaulting others. His di-
agnosis at discharge was psychotic disorder, NOS.
The third hospitalization occurred at age 8, also for acting
out and aggressive behavior, although the treatment records
were unavailable from this hospitalization. He was appar-
ently discharged to a residential treatment center at the end
of this hospitalization.
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Chief Complaint and Presenting Problem
S.is a 16-year-old adolescent boy with Tourette’s Dis-order (TD) referred to our clinic through family friends.
The parents reported that S. was currently hospitalized for
severe tics at a medical center. They were seeking additional
consultation and follow-up treatment.
History of Present Illness
The parents reported that S. had low-pitched vocalizations
since about age 3 or 4 years. The parents report that they
consulted their pediatrician who said that S. would ‘‘out-
grow’’ the sounds. S. subsequently went on to develop com-
plex finger movements and some intermittent throat clearing.
At no time did these sounds or movements cause distress or
interfere with S.’s functioning in any way. However, in the
summer when S. was 13 years old, he developed the onset of
forceful mouth opening movements. The parents report that
there were no unusual stresses, illnesses, or changes in S.’s life
at that time. The forcefulness of the mouth opening gradually
increased, and S. subsequently developed episodes in which
he would ‘‘space out.’’ The parents reported that there were
times when S. would not remember things that had hap-
pened. On occasion, S. would fall and then complain that he
did not know how he got from one place to the other. Ad-
ditionally, in the year prior to presentation, S. reportedly had
a seizure and fell off a gas scooter, losing consciousness and
fracturing an arm. S. had been wearing a helmet and did not
experience head trauma, but reported that he ‘‘blacked out’’
while riding the scooter, leading to the crash. S. was hospi-
talized and underwent a 72-hour video EEG, which showed
no seizure activity. He was also evaluated by a pediatric
neurologist who recommended an empiric trial of oxcarba-
zepine, even though there were no seizures observed during
the video EEG. A cardiac workup was normal, including
normal EKG and echocardiogram.
The parents reported that immediately after the oxcarba-
zepine was begun, S.’s tics increased significantly, including
much more forceful mouth opening, arm and shoulder
movements, and head and neck movements. He had a pri-
mary complex tic that comprised of a sequence of both motor
and vocal tics, beginning with a premonitory sensation of
general overall tension, leading to an urge to stretch his neck.
After stretching his neck and throwing his head backwards,
the tic included mouth opening, muscle stretching in his up-
per body, fist clenching, feet stretching, and rubbing his face.
During this time, the vocal component included cursing with
the ‘‘F’’ word followed by throat clearing, squeaking, and a
‘‘sh’’ sound. When asked about potential precipitants of the
tics, S. readily reported that stress was a trigger.
S. was taken off oxcarbazepine and switched to levetir-
acetam, which also did not seem helpful as the movements
continued to worsen. S. was evaluated by another neurologist
who reportedly recommended discontinuation of the leve-
tiracetam and another outpatient video EEG, which again
revealed no seizure activity. S. was subsequently treated with
clonidine, clonazepam, and guanfacine, all of which were not
helpful as per mother.
Through family friends, S. was referred to a movement
disorder specialist. At that time, S. was diagnosed with
Tourette’s Disorder (TD), and treatment was started with
risperidone and benztropine. For approximately five months,
S.’s tics essentially remitted. However, he gained a significant
amount of weight during this time. He also became de-
pressed, lethargic, and developed suicidal ideation, according
to his parents, but did not actually try to act on the suicidal
thoughts or harm himself.
During the several months prior to presentation to our
clinic, parents reported that S. had only occasional head and
neck thrusts and occasional coprolalia, but not nearly to the
degree that he had these symptoms in the previous six
months. During this time, S. was referred to a child and ad-
olescent psychiatrist who diagnosed anxiety. S. was started on
fluoxetine, which was gradually increased to his current dose
of 30mg. Parents report that this has been helpful for him.
S. asked to go off the risperidone two months prior to
presentation to our clinic because of mood problems and
weight gain. According to his parents, the medication was
tapered and discontinued, and S.’s tics gradually got worse in
one month prior to presentation. The head and neck thrusting
movements increased, and S. reportedly developed a rotatory
component. In an attempt to switch to a medication with less
weight-gain potential, ziprasidone was prescribed up to
80mg twice a day (bid) for about a month, with very little
1NYU Child Study Center, New York, New York.
2New York University School of Medicine, New York, New York.
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evaluated and found to have no sequelae. For the first con-
cussion, MRI or CAT scan was normal. For the second, S. was
hospitalized after his reported seizure and broken arm.
Otherwise, there has been no history of surgery or chronic
medical illnesses including thyroid, cardiac, asthma, or dia-
betes. S. has no allergies.
S. eats a typical adolescent diet and has recently started
an exercise program. He was described as having grown 12
inches and gained significant weight between ninth and tenth
grade, but gained much more weight in the past six months
when he was treated with risperidone.
S. is described as an adolescent who sleeps generally
soundly but has had some episodes of sleepwalking. He is
also described as a restless sleeper who kicks the blankets and
sheets off the bed at night.
Medication History
S. had been treated with numerous medications, although
for relatively brief durations, including oxcarbazepine, leve-
tiracetam, clonidine, clonazepam, guanfacine, haloperidol
and tetrabenazine. He reportedly became ‘‘stiff’’ on haloperi-
dol; a trial of tetrabenazine six months prior to presentation at
a maximum dose of 37.5mg bid resulted in severe depression
with suicidal ideation, although S. was not treated at the time
with an antidepressant. Risperidone treatment was effective
but complicated by lethargy, weight gain, elevated prolactin
(up to 65 ng=mL resulting in galactorrhea), and depression. S.
was treated for three to four days with olanzapine, and then
for one to two weeks with aripiprazole 10mg bid. with little
effect. Fluoxetine was added to the risperidone prior to pre-
sentation; this was reported to be beneficial for S.’s anxiety
and mood symptoms.
Medications on Presentation to the Clinic
Risperidone 5mg by mouth daily; fluoxetine 40mg daily;
benztropine 0.5mg bid; topiramate 50mg bid; fish oil 1000mg
bid.
Mental Status Examination on Presentation
to the Clinic
S. was evaluated with his mother and grandfather in the
room. He was a tall, muscular, casually but neatly dressed
adolescent with glasses who looked his appropriate age of 16.
S. was generally pleasant and cooperative. He appeared a bit
sedated with mild bradykinesia. The conversation was unin-
terrupted until S. had an episode of unresponsiveness when
the discussion centered on the phenomenon of tics. At this
point, S. stared off into space for approximately 1–2 minutes,
not responding to mother’s questions. After approximately
2 minutes, S. resumed the conversation but could not elabo-
rate on his experience during the interruption.
He denied current depressed mood, and his affect was re-
active. He denied suicidal or homicidal ideation and further
denied any perceptual disturbance, including no auditory or
visual hallucinations. His thought process was linear, and his
thought content was as described above with no obvious
delusions.
After about one hour, S. experienced one tic epis de, lasting
for about 5minutes. The episodewas begun by int rruption of
conversation, following by a backward dystonic type neck
arch. S. thrust his head backward, clenched his fists bilater-
ally, and stretched both of his legs out. He then began to open
his mouth forcefully, followed by forced vocalizations of the
‘‘F’’ word at a fairly loud pitch on a scale of 3–4þ . After the
‘‘F’’ word, he made other vocalizations that ended in a ‘‘sh’’
sound. At the end of the sequence, he squeezed both cheeks
with each hand rather intensely. There was no self-injurious
behavior during this tic episode. S. attempted to take deep
breaths during the episode upon advice to try to relax. S.
relaxed and resumed normal discussion after the 5 minute
episode. He did acknowledge having had the premonitory
experience of feeling tension build up within him before the
tic sequence.
Rating Scales
The Yale Global Tic Severity Scale (YGTSS) was adminis-
tered at the time of presentation. S.’s total tic score was 40,
with 20 on motor tics and 20 on vocal tics, with an overall
impairment rating of 50, given his home-schooling and recent
hospitalization due to the severity of his tics.
Brief Formulation
In summary, S. is a 16-year-old adolescent boy referred by
his parents for a history of severe TD requiring hospitalization
to manage his tics. By history, he also appeared to meet cri-
teria for obsessive-compulsive disorder (full or sub-threshold),
generalized anxiety disorder, and a major depressive episode
concurrent with risperidone. It also appeared possible, if not
likely, that S. experienced a depressive reaction or a major
depressive episode in the past during his transition to middle
school. Family history contributed a diathesis for TD, in that
there is a history of possible obsessive-compulsive symptoms
and affective disorder on the maternal pedigree. Medical his-
tory contributed a clinical diagnosis of seizure disorder, which
resulted in an arm fracture; there is also a significant history of
concussion twice in the past two years. It is possible, if not
likely, that either or both of these central nervous system dis-
orders were contributing to the severity of the current picture.
From a developmental perspective, S. was on a healthy tra-
jectory until the beginning of middle school and the transition
to early adolescence, during which he may have experienced
increased anxiety and possible mood difficulty. By history, he
has had extreme functional impairment secondary to tics in the
past year. On the positive side, S. has considerable strengths
including excellent academic performance, capacity for warm
object relationships, and supportive and resourceful parents
who are seeking to optimize his care.
Multi-Axial Diagnoses
Axis I: Tourette’s Disorder, severe to marked.
Obsessive-compulsive disorder, sub-threshold.
Generalized anxiety disorder.
Major depressive episode, secondary
to risperidone and tetrabe azin , past.
Axis II: Deferred.
Axis III: Seizure disorder, not otherwise specified.
Concussion twice within the past two years.
Fractured arm, past.
Axi IV: Level of psychosocial stressors: Sev re:
Hospitalized for tics and unable to attend
the school in the past year.
ADVANCED PEDIATRIC PSYCHOPHARMACOLOGY 471
Axis V: Current Global Assessment of Functioning
(GAF) Score: 40.
M st severe lifetime GAF: 40.
Follow Up Outpatient Tr atment Course
This is a summary of approximately one year of outpatient
treatment since S.’s presentation to our clinic. Initial recom-
mendations included behavioral, psychosocial, and pharma-
cologic interventions, each of which will be summarized
below.
Behavioral treatment
The behavioral component included a referral for habit
reversal training (HRT). S. attended several session of HRT
initially, and the therapy was effective for identification of his
premonitory urges and substitution of a competing response
for his simplemotor tics. However, it was not possible for S. to
extend these resul s to is complex tics that l sted 5–12 (or
longer) minutes in duration. S. discontinued HRT after four
sessions, as he and his parents were not convinced that it
would be helpful for his complex tics. Many months later, the
parents reported that his complex major tic could be stopped
at t e outs t with tickling of S. by one of them. However, S.’s
parents were concerned that tickling was only delaying and
then increasing the duration and intensity of what seemed to
be the inevitable major complex tic.
Psychosocial treatment
The major psychosocial intervention was to enroll S. in a
private school with very supportive staff and a small class-
room with other children with medical and=or neurologic
issues. After several years of enduring bullying and teasing in
public school, S. began to like school again, as evidenced by
his desire to go to school and an observable improvement in
his grades. Psychoeducation, including referral to the Tour-
ette Syndrome Association, and support for the family and S.
was also helpful.
Pharmacologic treatment
The family and S. were very concerned about weight gain
and galactorrhea, likely from risperidone. After extensive
discussions with S. and his parents, it was decided to attempt
to cross-taper S. from risperidone to fluphenazine in 1 milli-
gram increments, as S. had never had a trial with pimozide or
fluphenazine. This was initially successful, and S. tolerated
fluphenazine. The tics did not worsen as fluphenazine was
increased to 3mg total daily and risperidone decreased to
2mg total daily. However, upon decreasing the risperidone to
1mg and increasing fluphenazine to 4mg daily in the fourth
week of the cross-taper, S. had an exacerbation of tics. He had
been previously hospitalized when risperidone was reduced
below 2mg daily, and this was therefore the second exacer-
bation of his tics with a decrease in risperidone below a 2mg
threshold. Subsequently, risperidone was restored to 2mg
daily, and fluphenazine decreased back to 3mg daily, with
resolution of the tic exacerbation. S. remained stable on these
twomedications for approximately four months; his prolactin
levels were noted to decrease slightly from 65ng=mL to
45 ng=mL, although he continued to have mild galactorrhea
and weight gain. He had one spontaneous episode of de-
pression with tearfulness and hopeless feelings, with no sui-
cidal ideation, approximately five months after starting
treatment. This prompted an increase in his fluoxetine to
50mg daily with good effect. There was also one spontaneous
episode of urinary retention that resolved naturally but
prompted r d tion of his benztropine to 0.5mg daily.
Weight gain was an ongoing problem during the course of
outpatient treatment, although lipid and glucose profiles re-
mained i the normal range. Diet and exercise were encour-
aged at every visit, and the parents and S. tried various diets.
Exercise was usually difficult to do for S. as he was sedated on
medication andhad to be accompanied byhis parents or school
staff at all times. About four months into outpatient treatment,
topira ate was increased for further appetite suppression.
This was helpful in terms of suppressing his appetite; how-
ever, S. had a tic exacerbation that the parents felt was associ-
ate with the increase of topiramate to 75mg bid. Topiramate
was discontinued, despite the treatment team’s opinion that
there was a favorable benefit risk ratio. Through the course of
outpatient tr atment, S. experienced a total weight gain of 50
pounds. Other options are under consideration.
After approximately sevenmonths of outpatient treatment,
S. had a spontaneous worsening of tic symptoms with no
apparent precipitant and no change in his medications. S.’s
major complex tic increased to 6–14 minutes, and began to
occur 2–5 times daily. New self-injurious tics emerged, in-
volving hitting himself in the chest and head with his hands
bilaterally. Initially, this tic exacerbation was managed with
addition of clonazepam 0.5mg bid–tid, and with increase of
fluphenazine to 2mg AM and 3mg PM, and risperidone 1mg
bid. S. and his parents were reluctant to increase the risper-
idone because S.’s tics continued to worsen, and he continued
to gainweight. It was still theoretically possible to increase the
fluphenazine to even higher doses; however, the parents and
S. were very distraught about his tics. They began to inquire
about surgical options for the treatment of TD, including deep
brain stimulation, which is indicated only for adults with
treatment refractory illness (Larson 2008). It was felt that S.
was not treatment-refractory at that time, as he had not yet
had a trial of pimozide or some other medication interven-
tions.
A pimozide trial was begun cautiously in one mg incre-
ment titrations per week with weekly EKG monitoring, as S.
was concurrently taking fluoxetine 50mg daily. Pimozide is
metabolized primarily by CYP 450 3A4, so it was expected
that its concentration would be elevated, with potential in-
crease in QTc interval, due to inhibition of its hepatic
metabolism by fluoxetine. In the first twoweeks following the
addition of pimozide, there was no benefit and no QTc pro-
longation noted. However, S.’s tics were worsening, so it was
decided to hospitalize him due to his severe and self-injurious
tics and to more quickly increase the pimozide in a monitored
setting. Clonazepam was also increased to 0.5mg daily. On
admission, S.’s QTc was in the normal range, but after in-
creasing the pimozide to 3mg total daily (and decreasing the
fluphenazine to 1mg by mouth in the morning and 3mg by
mouth in the evening) S.’s QTc interval increased over two
days to 467 msec, beyond the upper limit of normal (450
msec). He was evaluated by cardiology, and it was re-
commended that the pimozide be discontinued, along with
discontinuation of the fluoxetine. The pimozide and fluoxe-
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aid in counseling for these CNVs, we calculated empiric esti-
mates for penetrance on the basis of the CNV frequencies in 
our population of postnatal microarray-based comparative 
genomic hybridization samples and in control populations.
MATERIALS AND METHODS
We examined postnatal specimens received by our laboratory, 
mostly from the United States, for clinical microarray-based 
comparative genomic hybridization between March 2004 and 
April 2012. !e analysis of indications for study among sam-
ples received in the "rst quarter of 2008 and of 2011 showed 
that 51–54% of individuals have developmental delay/intellec-
tual disability and 10–11% have epilepsy, whereas cases with 
autism spectrum disorders have increased from 10% to 14%, 
those with congenital anomalies have increased from 16% to 
23%, but those with dysmorphic features have decreased from 
25% to 16%. Cases with unspeci"ed indications for study have 
decreased from 7% to 5%. !ese are likely underestimates of 
actual phenotypes because not all phenotypic features are 
recorded on the test requisition form. !e array platform used 
depended on the date of specimen receipt because array designs 
changed over time. Samples were tested on targeted, bacte-
rial arti"cial chromosome–based arrays (SignatureChip ver-
sions 1–4; Signature Genomic Laboratories, Spokane, WA; n = 
15,411), whole-genome, bacterial arti"cial chromosome–based 
arrays (SignatureChipWG versions 1–2; Signature Genomic 
Laboratories; n = 8,113), or whole-genome, oligonucleotide-
based arrays (SignatureChipOS version 1; manufactured by 
Agilent Technologies, Santa Clara, CA; SignatureChipOS ver-
sions 2–3; manufactured by Roche NimbleGen, Madison, WI; 
all custom designed by Signature Genomic Laboratories; n = 
25,113) according to previously described methods.9–12 For the 
CNVs analyzed here, the targeted, bacterial arti"cial chromo-
some–based arrays only had coverage of 22q11.21 and proxi-
mal 1q21.1, whereas the whole-genome arrays had coverage of 
all studied CNVs. Frequencies for 15q11.2 deletions were cal-
culated only for cases studied on oligonucleotide-based arrays 
because the CNV was initially interpreted as likely benign and, 
therefore, not captured in our database for the cases studied 
with bacterial arti"cial chromosome–based arrays. For deter-
mination of CNV frequencies, only those CNVs that are of the 
recurrent size, as determined within the limits of resolution of 
Table 1 Penetrance estimates with case and control frequencies for recurrent CNVs
Region (gene 
within region)
Copy 
number
Coordinates  
(hg18)
Frequency,  
postnatal aCGH 
cases
Frequency,  
controls
P value  
(Fisher exact  
one-tailed test)
Frequency of  
de novo 
occurrence in 
cases
Penetrance 
estimate, % 
(95% CI)
Proximal  
1q21.1 (RBM8A)
Duplication chr1:  
144.0–144.5 Mb
85/48,637 (0.17%) 10/22,246 (0.04%) <<0.0001 0/13 (0%) 17.3 (10.8–27.4)
Distal  
1q21.1 (GJA5)
Deletion chr1:  
145.0–146.35 Mb
97/33,226 (0.29%) 6/22,246 (0.03%) <<0.0001 7/39 (17.9%) 36.9 (23.0–55.0)
Distal  
1q21.1 (GJA5)
Duplication chr1:  
145.0–146.35 Mb
68/33,226 (0.20%) 6/22,246 (0.03%) <<0.0001 5/30 (16.7%) 29.1 (16.9–46.8)
15q11.2 (NIPA1) Deletion chr15:  
20.3–20.8 Mb
203/25,113 (0.81%) 84/22,246 (0.38%) <<0.0001 0/27 (0%) 10.4 (8.45–12.7)
16p13.11 
(MYH11)
Deletion chr16:  
14.9–16.4 Mb
50/33,226 (0.15%) 12/22,246 (0.05%) <0.0005 5/23 (21.7%) 13.1 (7.91–21.3)
16p12.1  
(CDR2)
Deletion chr16:  
21.85–22.4 Mb
62/33,226 (0.19%) 16/22,246 (0.07%) <0.0002 1/28 (3.6%) 12.3 (7.91–18.8)
Distal 16p11.2 
(SH2B1)
Deletion chr16:  
28.65–29.0 Mb
46/33,226 (0.14%) 1/22,246 (0.005%) <<0.0001 7/21 (33.3%) 62.4 (26.8–94.4)
Distal 16p11.2 
(SH2B1)
Duplication chr16:  
28.65–29.0 Mb
35/33,226 (0.11%) 10/22,246 (0.04%) <0.01 1/8 (12.5%) 11.2 (6.26–19.8)
Proximal 16p11.2 
(TBX6)
Deletion chr16:  
29.5–30.15 Mb
146/33,226 (0.44%) 6/22,246 (0.03%) <<0.0001 33/47 (70.2%)a 46.8 (31.5–64.2)
Proximal 16p11.2 
(TBX6)
Duplication chr16:  
29.5–30.15 Mb
93/33,226 (0.28%) 9/22,246 (0.04%) <<0.0001 7/30 (23.3%) 27.2 (17.4–40.7)
17q12 (HNF1B) Deletion chr17:  
31.8–33.3 Mb
29/33,226 (0.09%) 2/22,246 (0.01%) <0.0001 5/9 (55.6%) 34.4 (13.7–70.0)
17q12 (HNF1B) Duplication chr17:  
31.8–33.3 Mb
37/33,226 (0.11%) 5/22,246 (0.02%) <0.0001 2/9 (22.2%) 21.1 (10.6–39.5)
22q11.21 (TBX1) Duplication chr22:  
17.2–19.9 Mb
136/48,637 (0.28%) 12/22,246 (0.05%) <<0.0001 12/47 (25.5%) 21.9 (14.7–31.8)
aCGH, microarray-based comparative genomic hybridization; CI, confidence interval; CNV, copy-number variation; <<, much less than.
aDeletions of the proximal 16p11.2 region showed a maternal transmission bias (14/68 mothers identified to be carriers vs. 0/38 fathers; two-tailed P = 0.0018, Fisher 
exact test); no parental transmission bias was detected for any other CNV.
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Purpose: Although an increasing number of copy-number varia-
tions are being identi#ed as susceptibility loci for a variety of pediat-
ric diseases, the penetrance of these copy-number variations remains 
mostly unknown. $is poses challenges for counseling, both for re-
currence risks and prenatal diagnosis. We sought to provide empiric 
estimates for penetrance for some of these recurrent, disease-suscep-
tibility loci.
Methods: We conducted a Bayesian analysis, based on the copy-
number variation frequencies in control populations (n = 22,246) and 
in our database of >48,000 postnatal microarray-based comparative 
genomic hybridization samples. $e background risk for congenital 
anomalies/developmenta  delay/intellectual disability was assumed 
to be ~5%. Copy-number variations studied were 1q21.1 proximal 
duplications, 1q21.1 distal deletions and duplications, 15q11.2 dele-
tions, 16p13.11 deletions, 16p12.1 deletions, 16p11.2 proximal and 
distal deletions and duplications, 17q12 deletions and duplications, 
and 22q11.21 duplications.
Results: Estimates for the risk of an abnormal phenotype ranged 
from 10.4% for 15q11.2 deletions to 62.4% for distal 16p11.2 dele-
tions.
Conclusion: $is model can be used to provide more precise esti-
mates for the chance of an abnormal phenotype for many copy-num-
ber variations encountered in the prenatal setting. By providing the 
penetrance  additional, critical information can be given to prospec-
tive parents in the genetic counseling session.
Genet Med 2013:15(6):478–481 
Key Words: copy-number variation; genomic disorder; microarray; 
penetrance; prenatal diagnosis
INTRODUCTION
Over the past several years, our understanding of copy-number 
variation (CNV) within the human genome and its relation to 
disease has rapidly evolved. Molecular cytogenetic techniques 
such as microarray-based comparative genomic hybridization 
have identi#ed disease-causing CNVs in a variety of disorders, 
ranging from ediatric disease (congenital anomalies, intel-
lectual disability, epilepsy, and autism spectrum disorders) to 
adult-onset conditions such as schizophrenia. Of note, many 
CNVs were identi#ed in multiple, variable disease cohorts, 
indicating that identical genetic changes could result in di"erent 
phenotypes.1,2 Furthermore, some of these CNVs were inherited 
from phenotypically normal parents.1,2 Although the genetics 
community was already familiar with variable expressivity in 
the classic example of 22q11.21 deletions, traditional cytoge-
netics had taug t us to use inhe itance f a genetic ch ge as 
a de#nitive factor for pathogenicity. Speci#cally, de novo aber-
rations are thought to be more deleterious, whereas inherited 
rearrangements (such as a marker chromosome) are considered 
more benign. However, for newly described CNVs like the dis-
tal 1q21.1 microdeletions/microduplications, despite variable 
phenotypes and inheritance from normal parents, enrichment 
of the CNVs among a"ected individuals in comparison with 
healthy controls implicated them as pathogenic.3 As increasing 
numbers of cases and controls are studied for CNVs, we are 
discovering many additional examples of these “predisposing,” 
or “susceptibility,” loci.1,2,4,5
Microarray analysis is now recommended as a #rst-tier test 
for many pediatric neurodevelopmental disorders.6,7 Postnatal 
identi#cation of one of these susceptibility CNVs explains at 
least one part of the genetic etiology of the disorder in the indi-
vidual, although additional factors, either genetic or environ-
mental, are likely to ultimately in%uence the phenotypic expres-
sion of these loci.1,8 Additional genetic factors, such as other 
CNVs, may be identi#ed via microarray testing, but in many 
cases, the other in%uences on the phenotype remain unknown. 
$is poses challenges to recurrence-risk counseling because 
subsequent children inheriting the CNV could have more or 
less severe, o  no, ph n typic consequences, and speci#c testing 
is not available to inform such predictions. In addition, as the 
use of microarrays in prenatal settings increases, fetuses with-
out a known family history of these CNVs will be identi#ed 
as carriers. $is can lead to counseling dilemmas and parental 
anxiety, especially in low-risk pregnancies, because the associ-
ated neurodevelopmental phenotypes cannot be ascertained 
prenatally and it is di!cult to quantify the risk to the fetus. To 
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Purpose: Although an increasing number of copy-number varia-
tions are being identi#ed as susceptibility loci for a variety of pediat-
ric diseases, the penetrance of these copy-number variations remains 
mostly unknown. $is poses challenges for counseling, both for re-
currence risks and prenatal diagnosis. We sought to provide empiric 
estimates for penetrance for some of these recurrent, disease-suscep-
tibility loci.
Methods: We conducted a Bayesian analysis, based on the copy-
number variation frequencies in control populations (n = 22,246) and 
in our database of >48,000 postnatal microarray-based comparative 
genomic hybridization samples. $e background risk for congenital 
anomalies/developmental delay/intellectual disability was assumed 
to be ~5%. Copy-number variations studied were 1q21.1 proximal 
duplications, 1q21.1 distal deletions and duplications, 15q11.2 dele-
tions, 16p13.11 deletions, 16p12.1 deletions, 16p11.2 proximal and 
distal deletions and duplications, 17q12 deletions and duplications, 
and 22q11.21 duplications.
Results: Estimates for the risk of an abnormal phenotype ranged 
from 10.4% for 15q11.2 deletions to 62.4% for distal 16p11.2 dele-
tions.
Conclusion: $is model can be used to provide more precise esti-
mates for the chance of an abnormal phenotype for many copy-num-
ber variations encountered in the prenatal setting. By providing the 
penetrance, additional, critical information can be given to prospec-
tive parents in the genetic counseling session.
Genet Med 2013:15(6):478–481 
Key Words: copy-number variation; genomic disorder; microarray; 
penetrance; prenatal diagnosis
INTRODUCTION
Over the past several years, our understanding of copy-number 
variation (CNV) within the human genome and its relation to 
disease has rapidly evolved. Molecular cytogenetic techniques 
such as microarray-based comparative genomic hybridization 
have identi#ed disease-causing CNVs in a variety of disorders, 
ranging from pediatric disease (congenital anomalies, intel-
lectual disability, epilepsy, and autism spectrum disorders) to 
adult-onset conditions such as schizophrenia. Of note, many 
CNVs were identi#ed in multiple, variable disease cohorts, 
indicating that identical genetic changes could result in di"erent 
phenotypes.1,2 Furthermore, some of these CNVs were inherited 
from phenotypically normal parents.1,2 Although the genetics 
community was already familiar with variable expressivity in 
the classic example of 22q11.21 deletions, traditional cytoge-
netics had taught us to use inheritance of a genetic change as 
a de#nitive factor for pathogenicity. Speci#cally, de novo aber-
rations are thought to be more deleterious, whereas inherited 
rearrangements (such as a marker chromosome) are considered 
more benign. However, for newly described CNVs like the dis-
tal 1q21.1 microdeletions/microduplications, despite variable 
phenotypes and inheritance from normal parents, enrichment 
of the CNVs among a"ected individuals in comparison with 
healthy controls implicated them as pathogenic.3 As increasing 
numbers of cases and controls are studied for CNVs, we are 
discovering many additional examples of these “predisposing,” 
or “susceptibility,” loci.1,2,4,5
Microarray analysis is now recommended as a #rst-tier test 
for many pediatric neurodevelopmental disorders.6,7 Postnatal 
identi#cation of one of these susceptibility CNVs explains at 
least one part of the genetic etiology of the disorder in the indi-
vidual, although additional factors, either genetic or environ-
mental, are likely to ultimately in%uence the phenotypic expres-
sion of these loci.1,8 Additional genetic factors, such as other 
CNVs, may be identi#ed via microarray testing, but in many 
cases, the other in%uences on the phenotype remain unknown. 
$is poses challenges to recurrence-risk counseling because 
subsequent children inheriting the CNV could have more or 
less severe, or no, phenotypic consequences, and speci#c testing 
is not available to inform such predictions. In addition, as the 
use of microarrays in prenatal settings increases, fetuses with-
out a known family history of these CNVs will be identi#ed 
as carriers. $is can lead to counseling dilemmas and parental 
anxiety, especially in low-risk pregnancies, because the associ-
ated neurodevelopmental phenotypes cannot be ascertained 
prenatally and it is di!cult to quantify the risk to the fetus. To 
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XLID-Causing Mutations and Associated Genes Challenged
in Light of Data From Large-Scale Human Exome Sequencing
Ame´lie Piton,1,2,4,* Claire Redin,1,2,4 and Jean-Louis Mandel1,2,3,*
Because of the unbalanced sex ratio (1.3–1.4 to 1) observed in intellectual disability (ID) and the identification of large ID-affected fam-
ilies showing X-linked segregation, much attention has been focused on the genetics of X-linked ID (XLID). Mutations causing mono-
genic XLID have now been reported in over 100 genes, most of which are commonly included in XLID diagnostic gene panels. Nonethe-
less, the boundary between true mutations and rare non-disease-causing variants often remains elusive. The sequencing of a large
number of control X chromosomes, required for avoiding false-positive results, was not systematically possible in the past. Such infor-
mation is now available thanks to large-scale sequencing projects such as the National Heart, Lung, and Blood (NHLBI) Exome
Sequencing Project, which provides variation information on 10,563 X chromosomes from the general population. We used this NHLBI
cohort to systematically reassess the implication of 106 genes proposed to be involved in monogenic forms of XLID. We particularly
question the implication in XLID of ten of them (AGTR2, MAGT1, ZNF674, SRPX2, ATP6AP2, ARHGEF6, NXF5, ZCCHC12, ZNF41,
and ZNF81), in which truncating variants or previously published mutations are observed at a relatively high frequency within this
cohort. We also highlight 15 other genes (CCDC22, CLIC2, CNKSR2, FRMPD4, HCFC1, IGBP1, KIAA2022, KLF8, MAOA, NAA10,
NLGN3, RPL10, SHROOM4, ZDHHC15, and ZNF261) for which replication studies are warranted. We propose that similar reassessment
of reported mutations (and genes) with the use of data from large-scale human exome sequencing would be relevant for a wide range of
other genetic diseases.
Introduction
Intellectual disability (ID, formerly called mental retarda-
tion) is a developmental brain disorder commonly defined
by an IQ below 70 and limitations in both intellectual
functioning and adaptive behavior. ID can originate from
environmental causes and/or genetic anomalies, and its
incidence in children is estimated to be of 1%–2%.1,2 As
a result of an excess of males affected by ID (the male-to-
female ratio is 1.3–1.4 to 1) and the identification of
many families presenting with a clear X-linked segrega-
tion, much attention has been focused for the last 20 years
on genes located on the X chromosome and thus respon-
sible for X-linked ID (XLID, previously known as XLMR)
when mutated.3,4 One of the first genes identified as
involved in XLID is FMR1 (MIM 309550), a target of the
unstable expansion mutation responsible for fragile X syn-
drome (MIM 300624); accounting for about 1%–2% of all
ID cases, this mutation still remains the most common
cause of XLID.5,6 Since then, the number of genes involved
in XLID when mutated has grown exponentially,3,7,8 from
only 11 in 1992 to 43 in 2002 and over 100 genes now
identified thank to the efforts of various teams.4,9,10 Half
of the known genes carrying mutations responsible for
XLID appear to be associated with nonsyndromic or pauci-
syndromic forms; the other half are associated with more
syndromic forms (i.e., ID associated with defined clinical
or metabolic manifestations), which facilitates the identifi-
cation of causative mutations in the same gene because
unrelated probands with comparable phenotypes can
bemore easily matched. However, the presence of ‘‘milder’’
mutations (in RPS6KA3 [RSK2, MIM 300075] or ARX [MIM
300382], for instance) and/or incomplete penetrance of
specific clinical signs in some individuals carrying muta-
tions in genes associated with syndromic ID can blur the
distinction between syndromic and nonsyndromic ID.11
Various approaches have been developed for the identi-
fication of genes and associated causative mutations
responsible for XLID (see Lubs et al.4 for a review): (1) po-
sitional cloning based on chromosomal rearrangements or
copy-number variants (CNVs) affecting the X chromo-
some, (2) screening of genes located in candidate intervals
identified via linkage analysis in large XLID-affected fam-
ilies, (3) direct sequencing of candidate genes with a func-
tion or expression pattern that suggests a role in cognition
or that fits with metabolic or clinical observations in
affected subjects, and (4) high-throughput sequencing al-
lowing screening of mutations in all protein-coding re-
gions of the genome or only in the X chromosome (exome
versus X exome).10,12–14
The validation of potentially damaging mutations in a
gene newly associated with XLID requires functional
and/or genetic analyses, especially when the identification
is based on reportingmutations in very few families or sim-
plex cases. Functional studies are uneven in pertinence
and strength. They can include direct assessment of the
mutational impact at any of the protein, cellular, or
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“Nonetheless,	  the	  boundary	  between	  true	  mutaSons	  and	  rare	  non-­‐disease-­‐
causing	  variants	  o]en	  remains	  elusive.	  The	  sequencing	  of	  a	  large	  number	  of	  
co trol	  X	  chromosomes,	  required	  for	  avoiding	  false-­‐posiSve	  results,	  was	  not	  
systemaScally	  possible	  in	  the	  past”.	  	  
	  
	  
“We	  propose	  that	  similar	  reassessment	  of	  reported	  mutaSons	  (and	  genes)	  
with	  the	  use	  of	  data	  from	  large-­‐scale	  human	  exome	  sequencing	  would	  be	  
relevant	  for	  a	  wide	  range	  of	  other	  geneSc	  diseases”.	  	  
	  

Utah,	  New	  York	  and	  Faroe	  Islands	  
VigneGe	  #1:	  Variable	  expressivity	  in	  any	  disease,	  
including	  in	  this	  one:	  	  Ogden	  Syndrome	  in	  	  
Ogden,	  Utah.	  
I
II 
III 
1 +/ 2 +/mt 
1 mt/ 
1
2 +/mt 
2 +/ 3 +/+ 4 mt/ 
3  +/mt 
5 7 mt/ 
4 5 +/mt 6 7 +/+ 8 +/ 
SB 
6 mt/ 
Am	  J	  Hum	  Genet.	  2011	  Jul	  15;89(1):28-­‐43.	  	  
VigneGe	  #2:	  Another	  family	  in	  Utah:	  New	  Syndrome	  
with	  Intellectual	  Disability,	  “AuBsm”,	  “ADHD”	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old
	  	  
Dysmorphic	  
Mental	  RetardaSon	  
“auSsm”	  
“ADHD”	  
Hearing	  diﬃculSes	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  geneSc	  tests	  negaSve,	  including	  negaSve	  
for	  Fragile	  X	  and	  MANY	  candidate	  genes.	  
•  Whole genome sequencing was performed using : 
–  Complete Genomics sequencing and analysis 
pipeline v2.0 
–  llumina HiSeq 2000 sequencing platform.  
•  Illumina reads were mapped to the hg19 reference genome 
using BWA v. 0.6.2-r126 
•  Variant detection was performed using the GATK v. 2.4-9.   
•  A second analytical pipeline was used to map reads to the 
hg19 reference genome using Novoalign, and variants were 
also detected using the FreeBayes caller. 
Using only nuclear family: 
55195 Variants were found to be de-novo in the two affected boys  
122 were coding : 
107 non-synonymous missense 
4 splicing  
3 frame-shift deletions 
3 frame-shift insertions 
2 frame-shift substitutions 
2 stop-gain  
1 stop-loss 
26514 Variants were found to conform to an X-linked disease model 
28 were coding: 
27 non-synonymous missense 
1 splicing 
Using information from a greater portion of the family structure: 
17726 Variants were found to be de-novo in the two affected boys  
40 were coding : 
32 non-synonymous missense 
3 splicing  
2 frame-shift deletions 
1 stop-loss 
1 frame-shift insertion 
1 frame-shift substitution 
2824 Variants were found to conform to an X-linked disease model 
4 were coding: 
3 non-synonymous missense 
1 splicing 
•  The	  numbers	  of	  mutaSons	  diﬀer	  as	  expected	  
between	  these	  two	  sets	  of	  analyses:	  	  
	  
– More	  mutaSons	  are	  ﬁltered	  when	  a	  greater	  
porSon	  of	  the	  family	  is	  incorporated	  into	  the	  
analysis.	  	  	  
	  
– This	  is	  likely	  due	  to	  false	  posiSve	  and	  false	  
negaSve	  rates	  across	  sequencing	  and	  informaScs	  
plamorms.	  
Using only nuclear family: 
De-novo ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 PRAMEF4 0.00192 0.00144,0.00265 13.13 chr1:12939476;13.13;G->C;N->K;0,1 
2 PRAMEF10 0.00318 0.00243,0.00417 20.77 chr1:12954852;20.77;T->C;H->R;3,2 
3 LOC440563 0.00523 0.00416,0.00653 9.89 chr1:13183056;9.89;T->C;N->D;0,1 
X-linked ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 ASB12 0.000898 0.000898,0.00119 18.7 chrX:63444792;18.70;C->A;G->C;0,1 
2 TAF1 0.00153 0.00117,0.00214 14.59 chrX:70621541;14.59;T->C;I->T;0,1 
3 ZNF41 0.002 0.0015,0.00275 12.9 chrX:47307978;12.90;G->T;D->E;0,1 
Using information from a greater  
portion of the family structure: 
De-novo ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 PRAMEF10 0.00342 0.00262,0.00445 20.77 chr1:12954852;20.77;T->C;H->R;3,2 
X-linked ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 TAF1 0.002 0.0015,0.00275 14.59 chrX:70621541;14.59;T->C;I->T;0,1 
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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
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in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
The	  two	  brothers	  with	  the	  P111L	  
mutaSons	  reported	  in	  the	  prior	  
paper	  do	  have	  mental	  deﬁciency,	  
hyperkinesia,	  no	  motor	  or	  
neurologic	  sign	  except	  for	  the	  
delay,	  and	  slight	  dysmorphic	  facial	  
anomalies:	  large	  low-­‐set	  ears,	  thin	  
upper	  lip,	  slight	  downward	  
palpebral	  slants,	  but	  no	  upturned	  
nose,	  and	  a	  short	  philtrum.	  The	  
mother	  was	  normal	  in	  appearance.	  	  
•  Previously	  reported	  P111L	  change	  in	  the	  ZNF41	  protein	  
has	  now	  also	  been	  found	  in	  two	  "male	  controls"	  (EVS	  
server,	  ESP6500),	  and	  furthermore,	  there	  are	  two	  rare,	  
likely	  heterozygous	  ZNF41	  frameshi]	  mutaSons	  and	  
one	  heterozygous	  stop-­‐gained	  mutaSon	  reported	  in	  
control	  individuals	  (ESP6500)	  (personal	  communicaSon	  
from	  Dr.	  Vera	  Kalscheuer).	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XLID-Causing Mutations and Associated Genes Challenged
in Light of Data From Large-Scale Human Exome Sequencing
Ame´lie Piton,1,2,4,* Claire Redin,1,2,4 and Jean-Louis Mandel1,2,3,*
Because of the unbalanced sex ratio (1.3–1.4 to 1) observed in intellectual disability (ID) and the identification of large ID-affected fam-
ilies showing X-linked segregation, much attention has been focused on the genetics of X-linked ID (XLID). Mutations causing mono-
genic XLID have now been reported in over 100 genes, most of which are commonly included in XLID diagnostic gene panels. Nonethe-
less, the boundary between true mutations and rare non-disease-causing variants often remains elusive. The sequencing of a large
number of control X chromosomes, required for avoiding false-positive results, was not systematically possible in the past. Such infor-
mation is now available thanks to large-scale sequencing projects such as the National Heart, Lung, and Blood (NHLBI) Exome
Sequencing Project, which provides variation information on 10,563 X chromosomes from the general population. We used this NHLBI
cohort to systematically reassess the implication of 106 genes proposed to be involved in monogenic forms of XLID. We particularly
question the implication in XLID of ten of them (AGTR2, MAGT1, ZNF674, SRPX2, ATP6AP2, ARHGEF6, NXF5, ZCCHC12, ZNF41,
and ZNF81), in which truncating variants or previously published mutations are observed at a relatively high frequency within this
cohort. We also highlight 15 other genes (CCDC22, CLIC2, CNKSR2, FRMPD4, HCFC1, IGBP1, KIAA2022, KLF8, MAOA, NAA10,
NLGN3, RPL10, SHROOM4, ZDHHC15, and ZNF261) for which replication studies are warranted. We propose that similar reassessment
of reported mutations (and genes) with the use of data from large-scale human exome sequencing would be relevant for a wide range of
other genetic diseases.
Introduction
Intellectual disability (ID, formerly called mental retarda-
tion) is a developmental brain disorder commonly defined
by an IQ below 70 and limitations in both intellectual
functioning and adaptive behavior. ID can originate from
environmental causes and/or genetic anomalies, and its
incidence in children is estimated to be of 1%–2%.1,2 As
a result of an excess of males affected by ID (the male-to-
female ratio is 1.3–1.4 to 1) and the identification of
many families presenting with a clear X-linked segrega-
tion, much attention has been focused for the last 20 years
on genes located on the X chromosome and thus respon-
sible for X-linked ID (XLID, previously known as XLMR)
when mutated.3,4 One of the first genes identified as
involved in XLID is FMR1 (MIM 309550), a target of the
unstable expansion mutation responsible for fragile X syn-
drome (MIM 300624); accounting for about 1%–2% of all
ID cases, this mutation still remains the most common
cause of XLID.5,6 Since then, the number of genes involved
in XLID when mutated has grown exponentially,3,7,8 from
only 11 in 1992 to 43 in 2002 and over 100 genes now
identified thank to the efforts of various teams.4,9,10 Half
of the known genes carrying mutations responsible for
XLID appear to be associated with nonsyndromic or pauci-
syndromic forms; the other half are associated with more
syndromic forms (i.e., ID associated with defined clinical
or metabolic manifestations), which facilitates the identifi-
cation of causative mutations in the same gene because
unrelated probands with comparable phenotypes can
bemore easily matched. However, the presence of ‘‘milder’’
mutations (in RPS6KA3 [RSK2, MIM 300075] or ARX [MIM
300382], for instance) and/or incomplete penetrance of
specific clinical signs in some individuals carrying muta-
tions in genes associated with syndromic ID can blur the
distinction between syndromic and nonsyndromic ID.11
Various approaches have been developed for the identi-
fication of genes and associated causative mutations
responsible for XLID (see Lubs et al.4 for a review): (1) po-
sitional cloning based on chromosomal rearrangements or
copy-number variants (CNVs) affecting the X chromo-
some, (2) screening of genes located in candidate intervals
identified via linkage analysis in large XLID-affected fam-
ilies, (3) direct sequencing of candidate genes with a func-
tion or expression pattern that suggests a role in cognition
or that fits with metabolic or clinical observations in
affected subjects, and (4) high-throughput sequencing al-
lowing screening of mutations in all protein-coding re-
gions of the genome or only in the X chromosome (exome
versus X exome).10,12–14
The validation of potentially damaging mutations in a
gene newly associated with XLID requires functional
and/or genetic analyses, especially when the identification
is based on reportingmutations in very few families or sim-
plex cases. Functional studies are uneven in pertinence
and strength. They can include direct assessment of the
mutational impact at any of the protein, cellular, or
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VigneGe	  #3:	  
A	  third	  family	  in	  Utah,	  with	  a	  40	  year	  old	  Caucasian	  
man	  with	  
very	  severe	  obsessive	  compulsive	  disorder,	  severe	  
depression	  and	  intermiRent	  psychoses,	  with	  symptoms	  
that	  started	  around	  age	  5.	  
	  
Sequencing	  and	  AnalyScs	  
From	  the	  Illumina	  Understand	  
Your	  Genome	  Symposium	  
October	  2012	  


Table 1.  A summary of three clinically relevant genetic aberrations found in the clinical sequencing results of M.A.  
Mutations in MTHFR, BDNF,  and ChAT were found to be of potential clinical relevance for this person, as they are all implicated in 
contributing to the susceptibility and development of many neuropsychiatric disorders that resemble those present within M.A.  A 
brief summary of the characteristics of each mutation is shown, including the gene name, genomic coordinates, amino acid change, 
zygosity, mutation type, estimated population frequency and putative clinical significance. 
 
Gene name Genomic coordinates Amino acid change Zygosity Mutation type Population Frequency Clinical significance 
MTHFR chr1: 11854476 Glu>Ala heterozygous non-synon T:77% G:23% 
Susceptibility to psychoses, 
schizophrenia, occlusive vascular 
disease, neural tube defects, 
colon cancer, acute leukemia, and 
methylenetetra-hydrofolate 
reductase deficiency  
BDNF chr11: 27679916 Val>Met heterozygous non-synon C:77% T:23% 
Susceptibility to OCD, psychosis, 
and diminished response to 
exposure therapy  
CHAT chr10: 50824117 Asp>Asn heterozygous non-synon G:85% A:15% 
Susceptibility to schizophrenia and 
other psychopathological 
disorders. 
   
No	  rare	  variants	  with	  high	  biological	  eﬀect	  as	  related	  to	  mental	  
illness.	  One	  variant	  related	  to	  Refsum	  Disease	  (involving	  vision).	  
	  
3	  common	  SNVs	  in	  this	  person	  that	  have	  been	  implicated	  in	  the	  
literatur 	  as	  predisposi g	  to	  mental	   llnes .	  


Nucleus	  accumbens	  
Fig.	  1.	  Coronal	  secSon	  of	  the	  brain	  near	  the	  nucleus	  accumbens	  with	  the	  track	  of	  
the	  electrodes	  on	  the	  le]	  and	  right	  side.	  
	  
2.5	  year	  follow-­‐up	  
Figure 2.   Yale Brown Obsessive Compulsive Scale (YBOCS) scores were measured 
for M.A  over a three year and seven months period of time.  A time series plot (A) 
shows a steady decline in YBOCS scores over the period of time spanning his DBS surgery 
(s) and treatment.   Incremental adjustments to neurostimulator voltage are plotted over a 
period of time following DBS surgery (A).  Mean YBOCS scores are plotted for sets of 
measurements taken before and after his Deep Brain Stimulation (DBS) surgery (B).  A 
one-tailed  unpaired  t  test  with  Welch’s  correction  results  in  a  p  value  of 
0.0056,  demonstrating  a significant difference  between YBOCS scores measured before 
and after the time of surgery.	
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  Assessment	  of	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Genotype	  ≠	  Phenotype	  
Environment	  maRers!	  
Ancestry	  maRers!	  
Genomic	  background	  maRers!	  
Longitudinal	  course	  maRers!	  
	  
You	  are	  extremely	  well-­‐posiSoned	  to	  study	  this	  	  in	  very	  
good	  fashion	  here	  in	  the	  Faroe	  Islands.	  
Take	  Home	  Message	  
